Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurIPFreg) and Biobank.
European Registry for Idiopathic Pulmonary Fibrosis (eurIPFreg)
electronic Nose (eNose, Aeonose®)
idiopathic pulmonary fibrosis (IPF)
interstitial lung diseases (ILD)
volatile organic compounds (VOC)
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Oct 2019
16 Oct 2019
Historique:
received:
24
08
2019
revised:
06
10
2019
accepted:
14
10
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
19
10
2019
Statut:
epublish
Résumé
There is an increasing interest in employing electronic nose technology in the diagnosis and monitoring of lung diseases. Interstitial lung diseases (ILD) are challenging in regard to setting an accurate diagnosis in a timely manner. Thus, there is a high unmet need in non-invasive diagnostic tests. This single-center explorative study aimed to evaluate the usefulness of electronic nose (Aeonose Exhaled volatile organic compound (VOC) signatures were obtained by Aeonose By dichotomous comparison of VOC's between ILD, COPD, and HC, a discriminating algorithm was established. In addition, direct analyses between the ILD subgroups, e.g., cryptogenic organizing pneumonia (COP, The Aeonose
Sections du résumé
BACKGROUND
BACKGROUND
There is an increasing interest in employing electronic nose technology in the diagnosis and monitoring of lung diseases. Interstitial lung diseases (ILD) are challenging in regard to setting an accurate diagnosis in a timely manner. Thus, there is a high unmet need in non-invasive diagnostic tests. This single-center explorative study aimed to evaluate the usefulness of electronic nose (Aeonose
METHODS
METHODS
Exhaled volatile organic compound (VOC) signatures were obtained by Aeonose
RESULTS
RESULTS
By dichotomous comparison of VOC's between ILD, COPD, and HC, a discriminating algorithm was established. In addition, direct analyses between the ILD subgroups, e.g., cryptogenic organizing pneumonia (COP,
CONCLUSIONS
CONCLUSIONS
The Aeonose
Identifiants
pubmed: 31623141
pii: jcm8101698
doi: 10.3390/jcm8101698
pmc: PMC6832325
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Breath Res. 2017 Jun 01;11(2):026006
pubmed: 28373602
Allergy. 2019 Mar;74(3):527-534
pubmed: 30156012
Chest. 2019 May;155(5):972-981
pubmed: 30742809
Eur Respir J. 2018 May 17;51(5):
pubmed: 29773606
Int J Mol Sci. 2016 Dec 23;18(1):
pubmed: 28025547
J Clin Med. 2019 May 09;8(5):null
pubmed: 31075945
Respir Res. 2018 Jul 28;19(1):141
pubmed: 30055613
Methods Mol Biol. 2018;1738:133-147
pubmed: 29654587
Acta Oncol. 2019 Sep;58(9):1216-1224
pubmed: 31311375
Trends Mol Med. 2015 Oct;21(10):633-644
pubmed: 26432020
Sensors (Basel). 2017 Nov 24;17(12):
pubmed: 29186754
Lung Cancer. 2018 Nov;125:223-229
pubmed: 30429025
Int J Chron Obstruct Pulmon Dis. 2015 Feb 23;10:399-406
pubmed: 25759572
Int J Chron Obstruct Pulmon Dis. 2018 May 01;13:1441-1448
pubmed: 29750030
J Breath Res. 2019 Mar 06;13(2):024001
pubmed: 30620934
BMC Pulm Med. 2018 Jan 25;18(1):19
pubmed: 29370786
Lancet. 2017 May 13;389(10082):1941-1952
pubmed: 28365056
Lung. 2017 Apr;195(2):157-165
pubmed: 28238110
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Respir Res. 2019 Mar 14;20(1):57
pubmed: 30871560
PLoS One. 2017 Jun 2;12(6):e0177678
pubmed: 28574989
J Breath Res. 2015 Dec 15;9(4):046002
pubmed: 26669708
Matrix Biol. 2018 Aug;68-69:404-421
pubmed: 29408012
BMC Pulm Med. 2019 Jul 18;19(1):130
pubmed: 31319833
ERJ Open Res. 2019 Apr 01;5(2):null
pubmed: 30949490
J Clin Med. 2018 Aug 06;7(8):null
pubmed: 30082599